Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease

Current Opinion in Gastroenterology

Volumn 21, Issue 4, 2005, Pages 454-460

  Tack, Jan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Gastroesophageal reflux disease; Proton pump inhibitor; Transient lower esophageal sphincter relaxations

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; BACLOFEN; PROTON PUMP INHIBITOR; VALPROIC ACID;

ANTIREFLUX OPERATION; DIAGNOSTIC ERROR; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENDOSCOPY; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM CARE; LOWER ESOPHAGUS SPHINCTER; MUSCLE RELAXATION; PATHOPHYSIOLOGY; PERISTALSIS; REVIEW; STOMACH ACID SECRETION; STOMACH FUNDOPLICATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTI-ULCER AGENTS; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; GABA AGONISTS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HUMANS; PROTON PUMPS;

EID: 21844442160     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Zentilin P, Dulbecco P, Bilardi C, et al. Circadian pattern of intragastric acidity in patients with nonerosive reflux disease (NERD). Aliment Pharmacol Ther 2003; 17:353-359.
2. Cadiot G,Bruhat A, Rigaud D, et al. Multivariate analysis of pathophysiological factors in reflux oesophagitis. Gut 1997; 40:167-174.
3. Gardner JD, Sloan S, Miner PB, Robinson M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17:945-953.
4. Schoeman MN, Tippett MD, Akkermans LM, et al. Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology 1995; 108:83-91.
5. Penagini R, Schoeman MN, Dent J, et al. Motor events underlying gastro esophageal reflux in ambulant patients with reflux esophagitis. Neurogastroenterol Mot. 1996; 8:131-141.
6. Piche T. des Varannes SB, Sacher-Huvelin S, Hoist JJ, Cuber JC, Galmiche JP. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology 2003; 124:894-902.
7. Sifrim D, Holloway R. Transient lower esophageal sphincter relaxations: how many or how harmful? Am J Gastroenterol 2001; 96:2529-2532.
8. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003; 290:66-72.
9. Murray L, Johnston B, Lane A, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol 2003; 32:645-650.
10. Kulig M, Nocon M, Vieth M, et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004; 57:580-589.
11. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004; 99:1652-1656.
12. Kahrilas PJ, Shi G, Manka M, Joehl RJ. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000; 118:688-695.
13. Van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000; 119:1439-1446.
14. Pandolfino JE, Shi G, Trueworthy B, Kahrilas PJ. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 2003; 125:1018-1024.
15. Fletcher J, Wirz A, Henry E, McColl KE. Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux. Gut 2004; 53:168-173. This is a conceptually important study, which demonstrates very high levels of acid exposure in the supra-junctional segment of the distal esophagus in health. The underlying mechanism is unclear. Studies in GERD and Barrett esophagus are eagerly awaited.
16. Anggiansah A, Taylor G, Bright N, et al. Primary peristalsis is the major acid clearance mechanism in reflux patients. Gut 1994; 35:1536-1542.
17. Williams D, Thompson DG, Marples M, et al. Identification of an abnormal esophageal clearance response to intraluminal distention in patients with esophagitis. Gastroenterology 1992; 103:943-953.
18. Achem AC, Achem SR, Stark ME, DeVault KR. Failure of esophageal peristalsis in older patients: association with esophageal acid exposure. Am J Gastroenterol 2003; 98:35-39.
19. Vinjirayer E, Gonzalez B, Brensinger C, et al. Ineffective motility is not a marker for gastroesophageal reflux disease. Am J Gastroenterol 2003; 98:771-776.
20. Simren M, Silny J, Holloway R, et al. Relevance of ineffective oesophageal motility during oesophageal acid clearance. Gut 2003; 52:784-790.
21. Malfertheiner P. Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease. Gut 2004; 53:312-313.
22. Richter JE. Effect of Helicobacter pylori eradication on the treatment of gastro-oesophageal reflux disease. Gut 2004; 53:310-311.
23. Jonaitis LV, Kiudelis G, Kupcinskas L. Characteristics of patients with erosive and nonerosive GERD in high-Helicobacter-pylori prevalence region. Dis Esophagus 2004; 17:223-227.
24. Queiroz DM, Guerra JB, Rocha GA, et al. IL1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis. Gastroenterology 2004; 127:73-79. This study demonstrates a negative association between GERD and H. pylori virulence factors and host proinflammatory cytokine polymorphisms.
25. Zentilin P, Iiritano E, Vignale C, et al. Helicobacter pylori infection is not involved in the pathogenesis of either erosive or nonerosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17:1057-1064.
26. Fallone CA, Barkun AN, Mayrand S, et al. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori. Aliment Pharmacol Ther 2004; 20:761-768.
27. Harvey RF, Lane JA, Murray LJ, et al. Bristol Helicobacter Project. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. BMJ 2004; 328:1417.
28. Muramatsu A, Azuma T, Okajima T, et al. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan. Aliment Pharmacol Ther 2004; 20(Suppl 1):102-106.
29. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 326:737.
30. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17:537-545.
31. Cicala M, Emerenziani S, Caviglia R, et al. Intra-oesophageal distribution and perception of acid reflux in patients with nonerosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 18:605-613.
32. Sarkar S, Thompson DG, Woolf CJ, et al. Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression. Am J Gastroenterol 2004; 99:1998-2006. This study suggests that central sensitization may contribute to symptomatic manifestations of GERD in some patients. Prolonged acid suppression may be able to reverse central sensitization.
33. Bardhan KD. The role of proton pomp inhibitors in the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther 1999; 9(suppl 1): 15-25.
34. Bautista J, Fullerton H, Briseno M, et al. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain-a randomized, double-blind, sham-controlled, crossover trial. Aliment Pharmacol Ther 2004; 19:1123-1130.
35. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140:518-527. This is a meta-analysis of studies evaluating the use of short-term PPI therapy as a diagnostic test for GERD. The authors conclude that symptomatic response to short-term PPI treatment does not confidently establish the diagnosis of GERD.
36. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940-1944.
37. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98:1487-1493.
38. Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93:763-767.
39. Katz PO, Anderson C, Khoury R, et al. Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12:1231-1234.
40. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98:545-550.
41. Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003; 17:1553-1558.
42. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterol 1998; 115:1335-1339.
43. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004; 2:656-664. This is a systematic literature review that confirms a decreased therapeutic response to PPIs in nonerosive reflux compared to erosive reflux disease.
44. Frazzoni M, De Micheli E, Zentilin P, Savarino V. Pathophysiological characteristics of patients with nonerosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20:81-88.
45. Gardner JD, Gallo-Torres H, Sloan S, et al. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 2003; 18:891-905.
46. Vela M, Camacho-Lobato L, Srinivasan R, et a. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599-1606.
47. Tamhankar AP, Peters JH, Portale G, et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg 2004; 8:890-897.
48. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99:981-988. This study confirms the importance of non-acid reflux for GERD symptoms that persist during PPI therapy.
49. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52:1397-1402.
50. Lehmann A, Antonsson M, Bremner-Danielsen M, et al. Activation of the GABAe receptor inhibits transient lower esophageal sphincter relaxations in the dog. Gastroenterology 1999; 117:1147-1154.
51. Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118:7-13.
52. Cantu P, Carmagnola S, Savojardo D, et al. Effect of non-selective gamma-aminobutyric acid receptor stimulation on motor function of the lower oesophageal sphincter and gastro-oesophageal reflux in healthy human subjects. Aliment Pharmacol Ther 2003; 18:699-704.
53. Tzovaras G, Tsiaoussis J, Athanasakis E, et al. Effect of sodium valproate on esophageal motility in healthy subjects and patients with gastroesophageal reflux. Scand J Gastroenterol 2004; 39:521-526.
54. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17:243-251.
55. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 52:464-470.
56. Lindeboom MA, Ringers J, Straathof JW, et al. Effect of laparoscopic partial fundoplication on reflux mechanisms. Am J Gastroenterol 2003; 98: 29-34.
57. Tam WC, Schoeman MN, Zhang Q, et al. Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease. Gut 2003; 52:479-485.
58. Tam WC, Holloway RH, Dent J, et al. Impact of endoscopic suturing of the gastroesophageal junction on lower esophageal sphincter function and gastroesophageal reflux in patients with reflux disease. Am J Gastroenterol 2004; 99:195-202.
59. Arts J, Tack J, Galmiche JP. Endoscopic antireflux procedures. Gut 2004; 53:1207-1214.
60. Johnson DA, Ganz R, Aisenberg J, et al. Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. Am J Gastroenterol 2003; 98:1921-1930.
61. Pleskow D, Rothstein R, Lo S, et al. Endoscopic full-thickness plication for the treatment of GERD: a multicenter trial. Gastrointest Endosc 2004; 59: 163-171.
62. Fockens P, Bruno MJ, Gabbrielli A, et al. Endoscopic augmentation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease: multicenter study of the Gatekeeper Reflux Repair System. Endoscopy 2004; 36:682-689.
63. Corley DA, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003; 125:668-676.
64. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease. JAMA 2000; 285:2331-2338.
65. Klaus A, Hinder RA, DeVault KR, Achem SR. Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course. Am J Med 2003; 114:6-9.
66. Papasavas PK, Keenan RJ, Yeaney WW, et al. Effectiveness of laparoscopic fundoplication in relieving the symptoms of gastroesophageal reflux disease (GERD) and eliminating antireflux medical therapy. Surg Endosc 2003; 17: 1200-1205.
67. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med 2003; 114:1-5.
68. Bloomston M, Nields W, Rosemurgy AS. Symptoms and antireflux medication use following laparoscopic Nissen fundoplication: outcome at 1 and 4 years. JSLS. 2003; 7:211-218.
69. Khaitan L, Ray WA, Holzman MD, Smalley WE. Health care utilization after medical and surgical therapy for gastroesophageal reflux disease: a population-based study, 1996 to 2000. Arch Surg 2003; 138:1356-1361.